Onconova Therapeutics Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Onconova Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ONTX, but not buy additional shares or sell existing shares.
View analyst ratings for Onconova Therapeutics or view top-rated stocks.

Wall Street analysts have given Onconova Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Onconova Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Onconova Therapeutics saw a decline in short interest in May. As of May 28th, there was short interest totaling 719,900 shares, a decline of 82.4% from the May 13th total of 4,080,000 shares. Based on an average daily volume of 1,410,000 shares, the days-to-cover ratio is presently 0.5 days. Currently, 4.9% of the company's stock are short sold.
View Onconova Therapeutics' Short Interest.

Onconova Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for Onconova Therapeutics.

Onconova Therapeutics, Inc. (NASDAQ:ONTX) issued its quarterly earnings results on Monday, May, 17th. The biopharmaceutical company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.15. The biopharmaceutical company earned $0.06 million during the quarter, compared to analysts' expectations of $0.06 million. Onconova Therapeutics had a negative net margin of 10,544.68% and a negative trailing twelve-month return on equity of 139.26%.
View Onconova Therapeutics' earnings history.

Onconova Therapeutics' stock was trading at $5.40 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ONTX shares have increased by 30.9% and is now trading at $7.07.
View which stocks have been most impacted by COVID-19.

Onconova Therapeutics shares reverse split before market open on Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 2021. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 20th 2021. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 7 shares after the split.

5 brokers have issued 1-year price objectives for Onconova Therapeutics' shares. Their forecasts range from $4.00 to $30.00. On average, they expect Onconova Therapeutics' share price to reach $18.06 in the next twelve months. This suggests a possible upside of 155.5% from the stock's current price.
View analysts' price targets for Onconova Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Onconova Therapeutics include Oncorus (ONCR), Viracta Therapeutics (VIRX), Neoleukin Therapeutics (NLTX), Tonix Pharmaceuticals (TNXP), Terns Pharmaceuticals (TERN), Fortress Biotech (FBIO), Foghorn Therapeutics (FHTX), ANI Pharmaceuticals (ANIP), Oramed Pharmaceuticals (ORMP), Verona Pharma (VRNA), Amryt Pharma (AMYT), Cue Biopharma (CUE), KemPharm (KMPH), Homology Medicines (FIXX) and Kala Pharmaceuticals (KALA).
View all of ONTX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Outlook Therapeutics (OTLK) and Actinium Pharmaceuticals (ATNM).

Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."

Onconova Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.89%), Renaissance Technologies LLC (1.56%), Millennium Management LLC (1.19%), Geode Capital Management LLC (0.87%), Principal Financial Group Inc. (0.53%) and Principal Financial Group Inc. (7.97%). Company insiders that own Onconova Therapeutics stock include 683 Capital Management, Llc, Abraham N Oler, E Premkumar Reddy, James J Marino, Jerome Groopman, Mark Patrick Guerin, Steven M Fruchtman and Tyndall Capital Partners L P.
View institutional ownership trends for Onconova Therapeutics.

ONTX stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Citadel Advisors LLC, Beacon Pointe Advisors LLC, and MONECO Advisors LLC.
View insider buying and selling activity for Onconova Therapeutics or view top insider-selling stocks.

ONTX stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, BlackRock Inc., Millennium Management LLC, Ikarian Capital LLC, Geode Capital Management LLC, Alyeska Investment Group L.P., HRT Financial LP, and Squarepoint Ops LLC. Company insiders that have bought Onconova Therapeutics stock in the last two years include Abraham N Oler, E Premkumar Reddy, James J Marino, Jerome Groopman, Mark Patrick Guerin, and Steven M Fruchtman.
View insider buying and selling activity for Onconova Therapeutics or or view top insider-buying stocks.

Shares of ONTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ONTX stock can currently be purchased for approximately $7.07.

Onconova Therapeutics has a market capitalization of $111.57 million and generates $230,000.00 in revenue each year. The biopharmaceutical company earns $-25,160,000.00 in net income (profit) each year or ($2.10) on an earnings per share basis.

Onconova Therapeutics employs 11 workers across the globe.

The official website for Onconova Therapeutics is www.onconova.com.

Onconova Therapeutics is headquartered at 375 PHEASANT RUN, NEWTOWN PA, 18940.

Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The biopharmaceutical company can be reached via phone at 267-759-3680 or via email at [email protected]